PEA3 Cooperates with C-Jun in Regulation of HER2/neu Transcription
Affiliations
HER2/neu overexpressing breast tumors exhibit an increase in polyomavirus enhancer activator 3 (PEA3) expression. We examined the relationship between HER2/neu transcriptional activation and PEA3 in cooperation with c-Jun. HER2/neu promoter activity was decreased by deleting PEA3 binding site, and was downregulated when the PEA3 binding site was mutated. PEA3 and c-Jun each weakly enhanced luciferase expression of the HER2/neu promoter. However, the HER2/neu promoter response to PEA3 was considerably enhanced by c-Jun. Thus, we examined the interaction of PEA3 with c-Jun by the two-hybrid system, the transcriptional activity of PEA3 was specifically enhanced by c-Jun. When PEA3, c-Jun and coactivator p300 were cotransfected in MCF7 cells, the transcriptional activity of HER2/neu was increased by up to 20-fold. PEA3 and c-Jun-induced transcription of HER2/neu promoter was repressed by cotransfection of the dominant negative of p300. These results suggest that PEA3 and c-Jun stimulated synergistically the HER2/neu gene transcription with p300.
Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in -mutant cancers.
Jansen R, Mainardi S, Dias M, Bosma A, van Dijk E, Selig R Proc Natl Acad Sci U S A. 2024; 121(9):e2319492121.
PMID: 38377196 PMC: 10907260. DOI: 10.1073/pnas.2319492121.
Inferring cancer common and specific gene networks via multi-layer joint graphical model.
Chen Y, Zhang X, Ou-Yang L Comput Struct Biotechnol J. 2023; 21:974-990.
PMID: 36733706 PMC: 9873583. DOI: 10.1016/j.csbj.2023.01.017.
Xue Z, Vis D, Bruna A, Sustic T, van Wageningen S, Batra A Cell Res. 2018; 28(7):719-729.
PMID: 29795445 PMC: 6028652. DOI: 10.1038/s41422-018-0044-4.
Rykala J, Przybylowska K, Majsterek I, Pasz-Walczak G, Sygut A, Dziki A Arch Med Sci. 2015; 11(3):619-27.
PMID: 26170857 PMC: 4495138. DOI: 10.5114/aoms.2013.35996.
Cantrell M, Ebelt N, Pfefferle A, Perou C, Van Den Berg C Oncotarget. 2015; 6(14):11863-81.
PMID: 25970777 PMC: 4494910. DOI: 10.18632/oncotarget.3787.